| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1038359552 |
| P356 | DOI | 10.1038/BJC.1998.295 |
| P932 | PMC publication ID | 2150313 |
| P698 | PubMed publication ID | 9667645 |
| P5875 | ResearchGate publication ID | 13616584 |
| P50 | author | David J. Waxman | Q30506493 |
| P2093 | author name string | K Gustafsson | |
| L J Yu | |||
| E G Brain | |||
| P Drewes | |||
| P2860 | cites work | Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study. | Q33484836 |
| Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. | Q34330493 | ||
| The history of the oxazaphosphorine cytostatics | Q34387919 | ||
| Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. | Q34411417 | ||
| Pharmacokinetics and molecular detoxication | Q34636589 | ||
| Ifosfamide, mesna, and nephrotoxicity in children | Q34730055 | ||
| Phenobarbital induction of cytochrome P-450 gene expression | Q35887158 | ||
| The human hepatic cytochromes P450 involved in drug metabolism | Q36258518 | ||
| 2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity | Q36291998 | ||
| DNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment | Q37661035 | ||
| Characterization of human microsomal cytochrome P-450 enzymes | Q38639934 | ||
| Structural basis of selective cytochrome P450 inhibition | Q40436955 | ||
| Species similarities and differences in pharmacokinetics. | Q41001138 | ||
| P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. | Q41142872 | ||
| Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes | Q41187611 | ||
| Pharmacologically guided phase I clinical trials based upon preclinical drug development | Q41197801 | ||
| Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy | Q41373234 | ||
| Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. | Q41462331 | ||
| Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics | Q41862432 | ||
| Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide | Q42285396 | ||
| Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene | Q42446376 | ||
| Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. | Q42556315 | ||
| 44 P450-catalyzed steroid hydroxylation: Assay and product identification by thin-layer chromatography | Q43723608 | ||
| Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats | Q44295730 | ||
| Mechanisms of cyclophosphamide action on hepatic P-450 expression | Q44848334 | ||
| Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene | Q45871076 | ||
| Suppression of rat hepatic microsomal cytochromes P450 by cyclophosphamide is correlated with plasma thyroid hormone levels and displays differential strain sensitivity. | Q51043067 | ||
| Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. | Q51053937 | ||
| Effect of microsomal activation on interaction between isophosphamide and DNA. | Q53826085 | ||
| Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. | Q54168667 | ||
| Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450 | Q58483717 | ||
| Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes | Q58483756 | ||
| Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes | Q58483760 | ||
| Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver | Q58483896 | ||
| Cytochrome P-450 isozyme 1 from phenobarbital-induced rat liver: purification, characterization, and interactions with metyrapone and cytochrome b5 | Q58483899 | ||
| Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas | Q69056912 | ||
| Dechloroethylation of ifosfamide and neurotoxicity | Q69889353 | ||
| Digitoxin metabolism by liver microsomal cytochrome P-450 and UDP-glucuronosyltransferase and its role in the protection of rats from digitoxin toxicity by pregnenolone-16 alpha-carbonitrile | Q70314957 | ||
| Studies on the pregnenolone-16 alpha-carbonitrile-inducible form of rat liver microsomal cytochrome P-450 and UDP-glucuronosyltransferase | Q70369026 | ||
| IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy | Q70423381 | ||
| Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs | Q70866441 | ||
| Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration | Q71046959 | ||
| Metabolite complex formation of orphenadrine with cytochrome P450. Involvement of CYP2C11 and CYP3A isozymes | Q71183963 | ||
| Interferon gamma down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes | Q71216118 | ||
| Hypoactivity of cytochrome P-450 after triacetyloleandomycin administration | Q72094207 | ||
| Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients | Q72108973 | ||
| Fluorometric determination of acrolein and related compounds with m-aminophenol | Q72290253 | ||
| Influence of phenobarbital induction on the enantioselective N-dechloroethylation of ifosfamide enantiomers in the rat | Q72345031 | ||
| Ifosfamide: should the honeymoon be over? | Q72516627 | ||
| Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy | Q72678270 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| ifosfamide | Q418560 | ||
| P304 | page(s) | 1768-1776 | |
| P577 | publication date | 1998-06-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo | |
| P478 | volume | 77 |
| Q31367858 | A novel class of antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), that releases 5-fluorouracil upon hypoxic irradiation |
| Q38824542 | Association of GSTT1 null, XPD 751 CC and XPC 939 CC genotypes with increased levels of genomic damage among hospital pathologists. |
| Q34093105 | Cancer therapy and polymorphisms of cytochromes P450. |
| Q40379518 | Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite |
| Q32117273 | Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites |
| Q34108043 | Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing |
| Q80510512 | DNA-binding agents |
| Q46784699 | Ifosfamide neurotoxicity: an atypical presentation with psychiatric manifestations. |
| Q37997025 | Impact of obesity on drug metabolism and elimination in adults and children |
| Q36360811 | Metabolism and transport of oxazaphosphorines and the clinical implications |
| Q74216286 | New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model |
| Q34113899 | Oxazaphosphorines: new therapeutic strategies for an old class of drugs |
| Q77830031 | Relationship between the kinetics of micronuclei induction and the mechanism of chromosome break formation by methylnitrosourea in mice in vivo |
| Q43964084 | Stem cell toxicity of oxazaphosphorine metabolites in comparison to their antileukemic activity |
| Q42698410 | Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study |
Search more.